This webinar provides an overview of the importance of accurate, reliable test results in patient care and public health research. It also explains how Clinical Standardization Programs support the use of clinical practice guidelines, enhance data interoperability, and help clinical laboratories and test developers ensure accurate testing that aligns with clinical practice guidelines for chronic diseases.
This webinar, hosted by the CDC's Division of Laboratory Systems and the OneLab Network, emphasizes the critical role of clinical standardization in ensuring laboratory test accuracy and comparability. Dr. Hubert Vesper explains how standardization prevents diagnostic errors and ensures that medical guidelines are applied consistently across different devices and laboratories to improve patient care.
Okay, everyone. We will go ahead and get started.
My name is Regina Jarrett, and I am a health education specialist in the Division of Laboratory
Systems DLS at CDC. A couple of notes before we dive into this webinar. If you're experiencing
any technical issues, feel free to email the OneLab inbox for support at onelabatcdc.gov.
If you have questions during this session, enter them in the Q&A section below the Q&A icon.
We'll hold a Q&A session at the very end of this presentation where we'll review questions,
do our best to answer them. And I've also posted a link to the live caption in the chat.
So please keep the caption window open if you use it in addition to the Teams webinar.
Today, we will open with a few words from Victor de Jesus, the Acting Director of the Division of
Laboratory Systems at the CDC. Then we'll introduce some of our OneLab resources and
today's speaker. We'll also have about a 10-minute Q&A session at the end where we'll review questions
and do our best to answer those questions. Today's session will end with a discussion
of upcoming network events. And for today's webinar, we will be leaving the chat feature open
for your engagement. When using the chat box, please keep the appropriate rules of engagement
in mind and feel free to use the chat to connect with others by reacting to what you've heard,
sharing experiences and asking questions to fellow participants. If you have questions
for the presenter today, please use the Q&A function, not the chat. Additionally,
please engage with respect and professionalism and any inappropriate language, improper conduct,
or discrimination may result in removal from this webinar. Please ensure your comments are relevant
to your topic if a moderator gives direction regarding chat behavior and please comply
accordingly. Please notify a moderator if you have experienced any technical difficulties or
observed any disruptive behavior. So, without further ado, I'll turn it now over to our OneLab
network lead, Alicia Branch. Thank you so much. I would like to wish our OneLab members a happy
lab week and it's my pleasure to introduce Dr. Victor De Jesus, the Acting Director of CDC's
Division of Laboratory Systems, who will provide the opening remarks. Over to you, Victor.
Thank you, Alicia. Good day to all of you. My name is Victor De Jesus and I am the Acting
Director of the Division of Laboratory Systems at the Centers for Disease Control and Prevention.
It is my pleasure to welcome you to today's OneLab Network event on how clinical
standardization programs advance the quality of laboratory testing. While in the U.S.,
CLIA regulations do not specifically address the use of standards, laboratory professionals
recognize that there is a role for clinical standardization programs and consensus standards
to help them strive for high-quality test systems. CDC's clinical standardization program's mission
is to improve the diagnosis, treatment, and prevention of selected diseases by standardizing
clinical laboratory measurements. These programs work to create measurement results
with the same analytical accuracy and precision to simplify comparison among them. I want to thank
our speaker, Dr. Hubert Vesper, for delivering today's valuable presentation. I also want to
thank the Division of Laboratory Systems staff who made this event possible. Dr. Branch, back to you.
Thank you so much. And thank you again for your warm remarks. Before the main presentation,
I'll introduce new OneLab resources and then read the PACE disclaimer. Next slide, please.
We're pleased to announce three new virtual reality specimen handling scenarios available
in OneLab VR and on Reach. These simulations provide users with the opportunity to enter
a virtual core laboratory to practice blood, urine, and respiratory specimens without the
risk of exposure to infectious substances. Next slide, please. In addition, we're highlighting
the What's the Total Testing Process video, which provides early career laboratory professionals
with an overview of the clinical testing cycle, including the pre-analytical, analytical,
and post-analytical phases. Links to both resources have been placed in the chat.
Next slide, please. Subject matter experts and presenters wish to disclose they have no
financial interests or other relationships with the manufacturers of commercial products,
suppliers of commercial services, or commercial supporters. I am excited to introduce – next
who is the Director of the Clinical Standardization Program here at CDC,
where he leads national and international programs and activities to enhance patient care
through laboratory standardization and harmonization of clinical tests. Dr. Vesper provides
scientific leadership and technical expertise to initiatives focused on standardizing and
harmonizing disease biomarker measurements. He currently chairs ISO TC212 Working Group 2,
overseeing the development of ISO standards for reference laboratories and materials.
He also is the co-chair of the Partnerships for Accurate Testing of Hormones, better known as
PATH, coordinating education efforts among stakeholder organizations to promote quality
and clinical testing and standardization. With over 100 publications, including eight
clinical laboratory and practice guidelines and recommendations, Dr. Vesper is a recognized leader
in the clinical laboratory test standardization, and he looks forward to presenting on the CDC's
Clinical Standardization Program and their impact on improving patient care and laboratory
testing. Our speaker for today is Dr. Hubert Vesper. Over to you, Dr. Vesper.
Thank you. Let me share my screen. Can you all see my screen?
We can.
Okay. Well, thank you for the very nice introduction, and as I would like to thank
the organizers of OneLab for giving me the possibility to talk about CDC's Clinical
Standardization Programs. In my presentation, I will talk about why we conduct these standardization
programs, how they relate to proficiency testing, and describe more in detail how we operate these
programs. For those not familiar with our programs, our focus is on chronic diseases,
and the five key areas that are covered by our programs are shown in the slide.
So, for example, for over 60 years now, we ensure that blood lipid measurements
conducted in the United States are accurate and reliable, and the instruments you use in
your laboratory to measure total cholesterol, they're calibrated and verified by our programs.
In addition to traditional blood lipids, we also cover lipoproteins,
such as alpha-little-A and E-protein B. The majority of analytes that we address
in our programs are hormones like thyroid hormones, parathyroid hormones, and vitamin D
for kidney and bone diseases, and steroid hormones for certain cancers and reproductive health.
In the area of diabetes, we are a reference laboratory for glucose and support a national
glycohemoglobin standardization program for A1c, and this program actually was designed
based on our cholesterol program. Our reference laboratories are ISO-accredited according to
ISO 15495 for clinical calibration laboratories, and our research labs,
where we conduct mainly epidemiological research, are CLIA-certified.
Now, before we start, let's do a poll. Do you think test results with FDA-approved tests
and operated in CLIA-certified labs are always accurate and compatible?
And you have four choices to choose from, so feel free to select one. Okay, I hope everybody was
able to select an answer for the first question. Do we have a feedback on the results? Yeah,
I don't hear anything. Did we get some feedback on the results from the poll?
We did. It's just showing on the screen. Oh, okay, because I'm presenting, I probably don't
see it. Yeah. Sure, I can read it off. By the way, you may want to read the report.
So, Hubert, we have 31% that mentioned it's highly accurate and comparable. We have 64%
indicating that it's somewhat accurate and comparable, and 0% for not confident in test
results, and about 6% said they don't know. Okay, very good. Well, those who voted somewhat
accurate would be correct. Some of the tests that we use in patient care are accurate and
compatible across devices. However, others aren't, and those are the tests that we are
particularly interested in our programmes. So, to further explain this, I'll choose vitamin D
as an example. Professional organisations recommend testing for vitamin D as part of
patient assessments, and so vitamin D testing has become the common analyte in clinical laboratories.
In this slide, I'd like to share observations we made in the 2018 College of American Pathologists
accuracy-based vitamin D survey, and this is a special survey offered by the CAP. It uses
non-modified pooled serum that was prepared in a manner to have characteristics as close as
possible to regular patient samples. In addition, this survey has vitamin D target values assigned
by the CDC reference laboratory, and in this slide, the target value for the particular sample
we will be looking at is indicated in the red line with a value of 57.06 nanomoles per litre.
So, I'm sorry about that. The blue bar indicates the highest and lowest value reported by a peer
group, and the orange line represents the median of the results reported by that particular peer
group. There were 12 peer groups in that particular challenge, and the results of
these peer groups are shown here with all tests passing this particular PT challenge,
but if you look at the orange bars, seven out of 12 participants have the majority of results
reported in a concentration range that would indicate that this sample, this patient has
inadequate vitamin D levels, while the reference values indicate that it actually is adequate.
I'd also like to point out that all peer groups use FDA-approved devices,
so being clear, certified, and using FDA-approved devices does not automatically ensure that all
the results are accurate and comparable across devices, or, you know, if you want to look at
the other way around, each time we compare a lab result to a general accepted decision point,
like in this case, the cut points issued by the National Academy of Medicine or former IOM,
measurements need to be consistent across devices, otherwise, cut points cannot be used appropriately.
Also, to put the vitamin D example in a different context, in 2022, CMS spent $257.5 million
on 8.8 million vitamin D tests, so vitamin D, in terms of cost, was the seventh-highest lab test
reimbursed by Medicare Part B, so we really need to make sure that results obtained with these
tests are accurate and reliable. I also want to point out that the analytes marked at the start
are analyzed data addressed by our standardization programs. Now, there are several hundred tests
in chemistry, at least, used in patient care, and while some of these tests are just fine,
others are in high need for standardization, and this slide shows some examples from professional
organizations pointing out problems with not only vitamin D, but also testosterone,
estradiol, thyroid hormones, and alkaline delay, and our standardization programs respond to these
situations by working with professional societies and the laboratory community
to improve the accuracy and reliability of the tests. And now, in general, the majority of
requests we actually receive to standardize and improve tests are from professional organizations,
and they point out that the high variability among tests either prevents the development of new
better guidelines or prevents the broad implementation of existing guidelines.
And before I go into details on how we conduct standardization, I'd like to talk
how proficiency testing and standardization activities relate to each other. Now,
with the PD for chemistry tests, we have typically two to three challenges per year,
and participants are grouped in peer groups, meaning labs using the same instrumentation,
and their results are compared to the results obtained in that peer group. And PD challenges
typically cover the whole testing process, from receiving the samples, analyzing them,
to reporting the results. And the assumption is that the laboratory or laboratories using
the same instrumentation should get the same results. In other words, proficiency testing
evaluates the lab using a particular device, not the agreement among peer groups. And the number
of labs combined in one peer group can differ from challenge to challenge, and only data from
one challenge are used in an evaluation. So by design, proficiency testing programs are typically
cross-sectional. On the other hand, CDC standardization programs only assess and evaluate
the analytical performance of an assay. And we compare the performance to predefined performance
criteria, such as allowable bias. And we don't evaluate per peer group, but we evaluate relative
to a metrological reference. Also, we look at performance of each participant over time as part
of the evaluation. So by design, standardization programs are typically longitudinal. The key is
that PT evaluates the whole testing process, and normally evaluates a lab relative to a peer group.
And this is because clinical laboratories typically cannot manipulate or modify the
instrumentation. And therefore, our standardization programs focus on the part that the lab cannot
modify, and proficiency testing providers typically do not evaluate.
And so our programs make sure that devices are accurate and reliable across peer groups.
And with that, PT and standardization programs complement each other. Now, moving on to our
standardization programs, in an ideal situation, the laboratory does not need to worry about whether
an IVD device is used, is standardized or not. In example, for A1c or total cholesterol,
all devices used in the United States are standardized and results are accurate and
compatible. However, for the hormones I mentioned earlier, standardized and non-standardized assays
are available and being used in patient care. And here, it is important to know whether the
assay is standardized. And this brings us to the next question. How familiar are you with
CDC's clinical standardization programs? And again, you have four choices to check,
so feel free to make your selections. Do we have some results back?
Yes, we do. So about 45% of the participants on the call are somewhat familiar. They are aware
of the concept and their importance. And about 30% are very familiar with our activities and
all these standardization efforts in their lab. And about another 20-25% of them have heard of
them or are not very familiar at all. Okay, very good. Well, those familiar with
our work, this will be a refresher. And those not familiar, I will explain our programs and
what we do more in detail. So the goal of our standardization programs is to improve patient
care by standardizing clinical laboratory measurements. And in other words, we focus
on the analytical performance, not the diagnostic performance of the test. And we do this by making
measurement results accurate and reliable and traceable to one accuracy basis, and therefore
comparable across devices, location, and over time. And it's important to understand that our
focus is on the measurement results, not technologies or procedures. So everybody can
use the test. If it's best in need, what we care about is really the results that comes out of the
test by that technology. Also, it is important to understand that standardization is an ongoing
process, not a single task. Initially, we work on improving the analytical performance, and then
we need to make sure we maintain it, because equipment and reagents change, and we need to
make sure that those changes don't affect the analytical accuracy. Also, to us, a standardized
test went through a thorough independent assessment and demonstrated that it meets analytical
performance goals. So IVD manufacturers and many laboratories use certified reference materials
for calibration and to check on the calibration of the assay. And while we recommend doing that,
one has to understand that this action might not be enough to ensure accuracy and comparability
across devices. I also want to point out that CDC is not developing analytical performance goals.
This is typically done by the laboratory and medical communities. We help and assist with
data and technical expertise, but the actual goals are developed by these communities,
and what we do is we adopt these analytical performance goals in our programs.
For standardization programs to be successful and useful to patient care and public health,
we need to conduct a range of activities that can be divided into three categories that are shown
here. First, we need to establish the tools needed for standardization. This is mainly
the development of reference methods and reference materials. And then in the second
part, we use these methods and materials and work with IVD manufacturers, laboratories,
and proficiency testing providers to improve the analytical performance of the assays.
And in the last step, we facilitate the integration of standardized assays in patient care.
And an example by developing new reference intervals based on standardized assays,
because when we recalibrate assays, the reference intervals need to be adjusted accordingly.
So I go over each category in the next slides. Now in our laboratory, we have reference methods
established or in development for the analytes listed in the first bullet here in the slide.
In terms of reference materials, we create mainly single donor serum that are not modified
and that were produced in a manner that makes them as close as possible to a regular patient
sample. We also support the production of traditional reference materials that are
available from NIST and other organizations. Those are pooled serum samples obtained from
multiple donors and are available typically at two or three different concentrations.
And to conduct assessments of analytic performance in a consistent and transparent manner,
we need protocols. And our protocols are based on CLSI protocols, such as CLSI EP9
for bias assessment. And we provide additional information on logistics and other details to
consistent execution of these protocols. The reference methods that we operate in our
laboratory are optimized for assay calibration and to verify the accuracy of IVD devices.
In other words, these methods are not intended for regular patient testing.
And to properly assess the accuracy of a device or calibrate a device properly,
our methods need to be highly accurate and precise. And this is illustrated in the table
here where we list our performance requirements for our reference methods. And for orientation,
we also provide performance requirements for routine tests as stated by CMS. So, for example,
for cholesterol, the maximum allowable bias and imprecision for our reference methods is 1%.
In this context, I would also like to point out that tests in red color for these tests,
we are the only reference laboratory in the United States that continuously operates these
reference methods. When it comes to actually improving the analytic performance,
we use a three-step approach. In the first step, we work with the lab or manufacturer and assess
analytic performance by doing basically method comparison studies. And here we provide serum
samples with values assigned by our reference methods. We typically provide 40 samples,
so participants can use CLSI EP9. However, we can't really provide any number of samples and
we have sets of 120 different samples for more detailed assessments. To claim an assay to be
standardized by our program, however, participants need to enroll in our certification programs.
Here, participants receive blinded samples that they analyze and report back to us.
We analyze the results and compare them to analytic performance goals,
and those who meet those goals will receive formal certificates and are considered standardized.
The certificate is valid for only a certain time and needs to be renewed.
Since certification is typically done at the manufacturer level, we monitor the
analytic performance at the laboratory or end-user level. And in this third step, we
make sure that improvements we made at the manufacturer actually reaches the end-user.
And these monitoring activities are done in our CDC accuracy-based monitoring programs,
and by collaborating with PT providers under accuracy-based PT programs. Earlier, I talked
about a thorough and independent assessment, and these slides provide some details of what we mean
by that. In our certification program, we use 40 single donor samples that cover the analytical
measurement range. By using 40 samples, we can also distinguish between calibration bias and
bias caused by non-specificity or other factors. We ask participants to provide
replicate measurements so we can assess the imprecision, and we perform quarterly challenges
where we send out 10 samples per quarter, and then we combine the data from four quarters to
make a final assessment. And by doing so, we also obtain information about performance over time.
Also, I'd like to point out that we customize the samples we provide, meaning each participant
gets a different set of samples, and we make sure the samples are all within the analytical
measurement range of the assay. And of course, we also conduct detailed data analysis trying
to eliminate possible clerical errors to the extent that we can identify them.
In our certification report, we provide very detailed information about the
analytical performance of the assay, and this slide just shows graphs from one page
of the report. This would be an example of a certification report from a testosterone
participant. The graph that I'm showing here is a bias plot with the x-axis showing the reference
values of all the 40 samples that we provide. Each circle represents one sample or the mean
of four replicate measurements, and the y-axis is the difference between the reported value
and the reference value as bias in percent. Now, when we look at the average bias across
all 40 samples and the bias distribution at the higher concentrations, when we see
something like that, we conclude that this assay is very well calibrated. However, when we look at
the lower concentrations, we see a much higher scatter of measurement bias, and typically
in situations like these, the assay has a problem with analytical selectivity or specificity
and analyte recovery. So, for the participant, this information is very helpful because they
know in order to improve their assay, they don't need to focus on fine-tuning the calibration,
but they really need to focus on minimising the non-specificity of the assay. And finally, we
provide very detailed information to our participants. We also provide a summary of
our findings on our website, and this table shown here is just a snapshot of one of the
tables we have on our website. This is for vitamin D. Now, being listed on our website
means that the assay meets the analytical performance criteria, and for vitamin D,
that would be a mean bias across 40 samples of plus-minus 5 percent and an imprecision of less
than 10 percent. And in addition to providing information about the assay itself, we also
provide information about the concentration range we tested and information about the individual
sample pass rate. Now, the individual sample pass rate can be used as an indicator of method
selectivity or analytical selectivity, and what it basically is is it is the proportion
of individual samples meeting the plus-minus 5 percent bias criterion. So, in this case,
90 percent of the 40 samples investigated meet the plus-minus 5 percent bias criterion.
Now, on our website, we have about 48 LDTs and immunoassays listed, and when we look at the
medium sample pass rate, about 32 percent of the average sample pass rate is 32 percent for
immunoassays and 65 percent for mass spectrometry assays. And, you know, what I want to bring across
here is, you know, even though assays are well-calibrated, we still have some work to do
in this particular case to improve the individual sample variability that we observe, especially
with vitamin D assays. Now, in this slide, the bias plots from all participants, certified and
non-certified, the data that we collected over the past 10 or so years are shown, and each dot
basically represents the mean of four replicate measurements. And the point I want to make here
is that every analyte is different and has different challenges. And so, we really need
to customise our programmes in order to not only improve the calibration bias, but also
to improve the scatter that we see here now with the individual samples, because ultimately,
we want to have all analytes to look like total cholesterol. Earlier, I mentioned that
standardisation is a process where we not only improve, but also maintain accurate and comparable
measurements. The figure on the left shows observations we made in our accuracy-based
LIPID programme. Here, we are looking at about 50 laboratories, they all use the same assay.
And at the beginning, the first couple of years, this assay was nice and accurate,
and then all of a sudden, the accuracy was thrifting. Now, in a patient care setting,
this small bias might not be of concern. However, if the trend continues, it might become a problem.
So, we informed the manufacturer who corrected the situation and results, and the measurement
bias is back on track. And so, because our reference methods are so accurate and precise,
we were able to detect these subtle changes early. And this is needed because our goal
with the monitoring programmes is to make sure that we can detect and address
possible trends early, before they become a problem in patient care.
Now, the figure on the right shows data that we collected from a laboratory-developed test.
Again, at the beginning, measurements where the bias was nice and everything was within
the limits, but then all of a sudden, the analytic performance deteriorated,
and upon further investigation, it turned out to be an operator problem.
The problem was resolved, the assay was back on track, but then all of a sudden, we saw again,
a more systematic shift in measurement bias, which turned out to be a calibration issue.
Now, by providing this kind of information to participants, in this particular situation,
the laboratory was able to improve the quality management system, and now provides better
training to lab staff and implement more strict calibrator batch comparisons before new batches
are being used. In terms of integrating standardisation in patient care and public
health, one main activity that we are conducting is developing reference intervals,
using standardised assays. The projects that are currently ongoing are development of reference
intervals, estradiol in post-menopausal women, and for testosterone in all women, and we also
work on improving paediatric reference intervals in general. Another area that is quickly developing
is with electronic health records, and here there's the broad implementation of electronic
health records that contain lab results, comparability across peer groups, or
interoperability of data becomes more important, because currently data from different labs and
healthcare systems are all combined in big data hubs, and people are now starting conducting
research using these lab data stored in these data hubs. Now, to make correct interpretation
of these data, standardisation now becomes even more important, and we work with stakeholders
to create awareness about the importance of standardisation in this area. This is drawn as a
nice example how standardisation in patient care and research help to develop and effectively
implement new practice guidelines. On the top of this graph, you have a regular patient care
setting, the patient visits the doctor, a test is being done, the test result is then being compared
to a cut of value from practice guidelines, and based on that comparison, an action is being
initiated. The guideline itself is based on research studies, where laboratory testing
was also conducted. And so, in our standardisation programmes, we not only improve the comparability
and accuracy of tests conducted in patient care, but also we work with principal investigators of
large clinical trials to make sure the testing conducted in these trials is accurate and
comparable. And then by having these data, in this case the Endocrine Society developed
evidence-based clinical guidelines with cut-off values based on standardised essays.
And because we have cut-off values based on standardised essays, as well as standardised
essays in patient care, clinical decision-making, or in other words, the implementation of these
practice guidelines is much more effective, to a point that payers now promote the use of
these guidelines in conjunction with standardised essays. Changing gears a little bit,
when we're monitoring the health of the US population to evaluate public health activities,
standardisation is very important. The graph here shows the prevalence of high cholesterol
and low HDL cholesterol in the US population over a period of 20 years. These data are obtained
in NHANES using five different essays. And we only can look at these trends with confidence
because all the essays used over the past 20 years were assessed and certified by our programmes,
and the laboratories conducting the measurements successfully participated in our accuracy-based
monitoring programmes. So therefore our programmes are not only beneficial in healthcare settings,
but also in public health, especially when it comes to assessing long-term trends in populations.
Coming back to proficiency testing, at the beginning I showed you some PT data
on vitamin D at the time when the vitamin D standardisation programme just started.
These are now data, proficiency testing data on testosterone at the time when we just started
with our testosterone standardisation programme. And shown here is the bias distribution of five
peer groups with the instrumentation used in peer group four being standardised at that point in
time. And the figure shows that standardised essays are more accurate than non-standardised
essays. But the important message here is to understand that standardised and non-standardised
essays are used in patient care right now with our distinction. And this is because our programme
is voluntary, so people are not required to participate. They typically participate because
quality of testing and accuracy is important to them. For the laboratory, it is important
to understand that when we have standardised and non-standardised essays available,
that when you use commonly established cut-off values, you need to know how accurate your essay
is in order to appropriately apply those cut-off values stated in clinical practice guidelines.
Also, I'd like to mention that the data that we produce are not only used by
essay manufacturers in laboratories, but also by FDA and CMS. They use our data to inform
decision-making. Also, medical organisations and healthcare payers see the benefits of
standardised tests and recommend using those tests in their guidelines and policies.
Now, what can the laboratory do to ensure that their tests are standardised?
Well, first you can check our website to find out if your essay is standardised, and we update our
website every quarter. You can also check the accuracy of your essays by using reference
materials or the reference services offered by our programmes. Or you can participate in
accuracy-based proficiency testing or monitoring programmes. And those programmes not only provide
you with information on how your test is performing, but also helps us with detecting
and addressing concerning trends early. So, in summary, CDC clinical standardisation programmes
ensure that measurement results are sufficiently accurate and reliable across devices and over time.
Our programmes are complementary to PTEQA programmes because we focus on analytical
performance across peer groups and improve parameters such as device calibration that
typically cannot be performed by the laboratory. Participation in our programme is voluntary,
and as a result, we have standardised and non-standardised essays available in patient care.
And it is important to know if an essay is standardised, especially when tests are compared
to clinical decision points mentioned in guidelines. And with that, I'm at the end of
my little presentation. I'd like to thank you all for listening, and of course, I'm here to answer
any questions you may have. Thank you. Okay, we'll take a few minutes to answer as many
questions as possible. If we're unable to answer your question today, we'll do our best to respond
by email. And if you have questions after today, please feel free to email them to the OneLab inbox
at onelabatcdc.gov. Let's see now. So I'll pick up this first question.
I already participate in PT and EQA. Do I also need to participate in the clinical
standardisation programme? If you have a regular in vitro diagnostic device,
the participation is normally done by the manufacturer.
So in US laboratory, you don't need to participate in our certification programme.
Please keep in mind when you
participate in a regular EQA programme, many times the samples in these EQA programmes
are highly modified. And so while you can compare your results within your peer group,
you don't have good information about how accurate your assay is compared to an assay
from a different manufacturer. For that, we recommend either participating in our accuracy
based monitoring programmes or the accuracy based proficiency testing programmes that are available
by PT providers. Okay. The next one is, what steps should the laboratory take to evaluate
and ensure the analytical accuracy of their test? Well, you need to do your regular testing for
clear purposes and with either calibration verification, for example, materials that
are provided by EQA providers or reference materials that you can purchase commercially.
If you cannot find a material or the material you feel is not suitable for your particular
assay, you can always send us an email or check with us, contact us so we can
see whether we can help you with the accuracy assessment of your assay.
Are certain technologies better than others?
Sometimes. What we observed is that, you know, I mentioned the example of vitamin D where
the sample specific pass rate is much lower for immunoassays than for mass spectrometry assays,
indicating that mass spectrometry assays might be more specific. One thing to keep in mind is that
we saw a lot of improvements with immunoassays over the years and so the technology that might
not be optimal right now might become better with the second or third generation of the assay.
So it's always good to look at the latest information that is available in terms of
measurement accuracy. And it also depends on the intended use of your assay. I know that some
laboratories use, for example, immunoassays for measurements of testosterone in men and
mass spectrometry assays for measurements of testosterone in women. So it really depends
on the application. But we do see mass spectrometry-based assays, for example,
also failing our programs. So a certain technology is not a guarantee for high-quality testing.
And one last question. If someone was interested in participating in the CDC
clinical standardization program, how would they go about contacting you or being a part of the
program? The easiest way to do is to send us an email at standardization at cdc.gov.
And the email is also shown here on my last slide. We monitor this email on a daily basis and
we will reach out to you to find out what you need and how we can help.
Thank you so much for joining us today. And we're sure to contact you again to
present on another OneLab event. Thank you. Pleasure to be here.
Next slide, please. Just a reminder, today's event is eligible for one hour of PACE credit.
However, our PACE credit is temporarily unavailable. So our efforts are underway
to reinstate PACE. And once it is reinstated, our eligible participants, those who have joined
today, will receive the instructions on how to obtain their certificate. Next slide.
We'd like to briefly highlight the next OneLab Network event, which will occur on June 10th
at 12pm. It's entitled Overview of Testing Personnel Qualification in Moderate and High
Complexity Testing. And it will be presented by CMS. Registration instructions and additional
event details will be shared soon. Next slide, please. As a reminder, the slides and audio
recording from today's event will be posted to our website within two weeks from today's event.
And finally, I encourage you all to use the OneLab inbox to share your training needs and
your feedback. We actually use your input to select event topics and to better understand the
community's needs. And also, if you're interested in serving as a pilot tester for our OneLab REACH
e-learning courses, the OneLab email address is also posted in the chat for easy access.
And I would like to say thank you. Again, have a great laboratory week.
And have a great rest of your day.